NKIAMRE Inhibitors primarily include chemicals that inhibit enzymes in the PI3K signaling pathway, such as PI3K itself, mTOR, and AKT. These inhibitors exert their effects through various mechanisms. Some, such as LY294002, Wortmannin, BKM120, PI-103, BEZ235, ZSTK474, and GDC-0941, directly inhibit PI3K, the key enzyme in the pathway NKIAMRE is involved in. The inhibition of PI3K disrupts the signaling cascade, which can lead to decreased functional activity of NKIAMRE as a downstream effector of this signaling pathway.
Other NKIAMRE inhibitors, including Rapamycin, AZD8055, Everolimus, and KU-0063794, target mTOR, a downstream component of the PI3K pathway. By inhibiting mTOR, these chemicals disrupt the PI3K signaling pathway, indirectly leading to decreased functional activity of NKIAMRE. A-443654 is an ATP-competitive inhibitor of AKT kinases, which are key components of the PI3K pathway. By inhibiting AKT, A-443654 can disrupt the PI3K signaling pathway,thus indirectly leading to decreased functional activity of NKIAMRE.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinases (PI3K). NKIAMRE is known to act in PI3K signaling pathways, and by inhibiting PI3K, LY294002 can lead to a decrease in the activity of NKIAMRE as a downstream effector. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent PI3K inhibitor. Its inhibition of PI3K disrupts the signaling pathway that NKIAMRE is involved in, leading to decreased functional activity of NKIAMRE. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
BKM120 is a specific and potent inhibitor of PI3K. By inhibiting PI3K, which is a key component of the signaling pathway NKIAMRE is involved in, BKM120 can lead to decreased functional activity of NKIAMRE. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), which is a downstream effector of the PI3K pathway. The inhibition of mTOR can disrupt the PI3K signaling pathway, thus indirectly leading to decreased functional activity of NKIAMRE. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent, selective, and bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor. Its inhibition of mTOR can disrupt the PI3K signaling pathway, thus indirectly leading to decreased functional activity of NKIAMRE. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor. Its inhibition of mTOR can disrupt the PI3K signaling pathway, thus indirectly leading to decreased functional activity of NKIAMRE. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a potent, cell-permeable, ATP-competitive and selective inhibitor of PI3K family members. By inhibiting PI3K, PI-103 can lead to decreased functional activity of NKIAMRE. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
BEZ235 is a dual PI3K/mTOR inhibitor. Its inhibition of both PI3K and mTOR can disrupt the PI3K signaling pathway, thus leading to decreased functional activity of NKIAMRE. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is a selective class I phosphatidylinositol 3-kinase inhibitor. Its inhibition of PI3K can lead to a decrease in the activity of NKIAMRE. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a potent, selective, bioavailable inhibitor of class I PI3 kinase. Its inhibition of PI3K can lead to a decrease in the activity of NKIAMRE. | ||||||